Cargando…
Association Between Peripheral Blood CD19-Positive Rate and Antibody-Mediated Rejection Following Rituximab Administration in Kidney Transplant Recipients
BACKGROUND. Rituximab is used widely for desensitization in ABO-incompatible and donor-specific antibody-positive kidney transplantation. However, data about the effects of individual differences in rituximab-induced B-cell suppression on antibody-mediated rejection (AMR) remain unknown. We aimed to...
Autores principales: | Nanmoku, Koji, Shinzato, Takahiro, Kubo, Taro, Shimizu, Toshihiro, Yagisawa, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616141/ https://www.ncbi.nlm.nih.gov/pubmed/31334341 http://dx.doi.org/10.1097/TXD.0000000000000907 |
Ejemplares similares
-
Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation
por: Parajuli, Sandesh, et al.
Publicado: (2017) -
Alloreactive T cells to Assess Acute Rejection Risk in Kidney Transplant Recipients
por: Mendoza Rojas, Aleixandra, et al.
Publicado: (2023) -
Efficacy and Safety of Tocilizumab in the Treatment of Acute Active Antibody-mediated Rejection in Kidney Transplant Recipients
por: Pottebaum, April A., et al.
Publicado: (2020) -
Utility of Serial Donor-derived Cell-free DNA Measurements for Detecting Allograft Rejection in a Kidney Transplant Recipient After PD-1 Checkpoint Inhibitor Administration
por: Lakhani, Laila, et al.
Publicado: (2021) -
Successful Desensitization of T cell Flow Cytometry Crossmatch Positive Renal Transplant Recipients Using Plasmapheresis and Super High-Dose Intravenous Immunoglobulin
por: Kakuta, Yoichi, et al.
Publicado: (2017)